First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Journal of Clinical Oncology · 2025-05 · 43 (13) · 1553-1563
DOI: 10.1200/jco-24-01269 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025-05. Verfasst von Pasi A Jänne und 19 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non–small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2, ClinicalTrials.gov identifier: NCT04129502 ) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of EGFR ex20ins+ advanced/metastatic NSCLC. METHODS Patients with treatment-naive EGFR ex20ins+ locally advanced/metastatic NSCLC were randomly assigned 1:1 to mobocertinib 160 mg once daily or pemetrexed plus cisplatin or carboplatin every 3 weeks for four cycles followed by maintenance pemetrexed. The primary end point was progression-free survival (PFS) by blinded independent central review (BICR), with planned interim analysis (IA) after approximately 70% of 227 expected PFS events. RESULTS A total of 354 patients were randomly assigned (mobocertinib: n = 179; chemotherapy: n = 175). Baseline characteristics were balanced between arms. At IA (cutoff: April 4, 2023), the median PFS per BICR was 9.6 months in each treatment arm (hazard ratio [HR], 1.04 [95% CI, 0.77 to 1.39]; P = .803). The primary end point crossed the prespecified futility boundary (HR > 1). The confirmed objective response rate (95% CI) per BICR was 32% (26 to 40) with mobocertinib versus 30% (24 to 38) with chemotherapy; the median duration of response was 12.0 versus 8.4 months. Quality-of-life assessments indicated clinically meaningful delays in time to deterioration of lung cancer symptoms, cognitive function, and constipation with mobocertinib versus chemotherapy. Grade ≥3 adverse events in >5% of patients (mobocertinib, chemotherapy) were diarrhea (20%, 1%), anemia (6%, 10%), increased lipase (6%, 0%), and decreased neutrophil count (1%, 7%). CONCLUSION The EXCLAIM-2 trial did not meet its primary end point. The efficacy of mobocertinib was not superior to platinum-based chemotherapy for first-line treatment of patients with EGFR ex20ins+ advanced/metastatic NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Guangdong Lung Cancer Institute, Guangzhou, China.
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- Sichuan Cancer Hospital, Chengdu, China.
- Klinik Floridsdorf, Vienna Healthcare Group and Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Vienna, Austria.
ORCID-Profile: Pasi A Jänne, Byoung Chul Cho, Juan Li, Solange Peters, Benjamin Besse, Nick Pavlakis, Joel W Neal, Terufumi Kato, Yi-Long Wu, Danny Nguyen, Junjing Lin, Jianchang Lin, Annette Szumski, Robert J Fram, Tony S K Mok
Zitieren
APA
Jänne, P. A., Wang, B. C., Cho, B. C., Zhao, J., Li, J., Hochmair, M., Peters, S., Besse, B., Pavlakis, N., Neal, J. W., Kato, T., Wu, Y. L., Nguyen, D., Lin, J., Lin, J., Vranceanu, F., Szumski, A., Lin, H. M., Fram, R. J., & Mok, T. S. K. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology, 43(13), 1553-1563. https://doi.org/10.1200/jco-24-01269
Vancouver
Jänne PA, Wang BC, Cho BC, Zhao J, Li J, Hochmair M, et al. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology. 2025;43(13):1553-1563. doi:10.1200/jco-24-01269
BibTeX
@article{Jnne2025,
author = {Jänne, Pasi A and Wang, Bin-Chao and Cho, Byoung Chul and Zhao, Jun and Li, Juan and Hochmair, Maximilian and Peters, Solange and Besse, Benjamin and Pavlakis, Nick and Neal, Joel W and Kato, Terufumi and Wu, Yi-Long and Nguyen, Danny and Lin, Junjing and Lin, Jianchang and Vranceanu, Florin and Szumski, Annette and Lin, Huamao M and Fram, Robert J and Mok, Tony S K},
title = {First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {13},
pages = {1553--1563},
doi = {10.1200/jco-24-01269}
}
EUVIMED